Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody-Reference-Cited by-同舟云学术

Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody

Published:2015-04-23 Issue:4 Volume:7 Page:778-791
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Singh Sanjaya,Kroe-Barrett Rachel R,Canada Keith A,Zhu Xiang,Sepulveda Eliud,Wu Helen,He Yaqin,Raymond Ernest L,Ahlberg Jennifer,Frego Lee E,Amodeo Laura M,Catron Katrina M,Presky David H,Hanke Jeffrey H

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

http://www.tandfonline.com/doi/pdf/10.1080/19420862.2015.1032491

Reference67 articles.

1. How Cytokine Networks Fuel Inflammation: Interleukin-17 and a tale of two autoimmune diseases

2. The IL-23–IL-17 immune axis: from mechanisms to therapeutic testing

3. The IL23/Th17 Pathway as a Therapeutic Target in Chronic Inflammatory Diseases

4. Relation of an interleukin-23 receptor gene polymorphism to graft-versus-host disease after hematopoietic-cell transplantation

5. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The immunologic role of IL-23 in psoriatic arthritis: a potential therapeutic target;Expert Opinion on Biological Therapy;2024-09-08

2. Low Placental Transfer Rates of Risankizumab Among Pregnant Women With Inflammatory Bowel Disease;Inflammatory Bowel Diseases;2024-08-31

3. Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: A Comprehensive Analysis from Clinical Trials;Dermatology and Therapy;2024-08-17

4. Biologics for Psoriasis;Dermatologic Clinics;2024-07

5. Population Pharmacokinetic and Exposure–Response Modeling to Inform Risankizumab Dose Selection in Patients With Ulcerative Colitis;Clinical Pharmacology & Therapeutics;2024-06-11